Document Type : Original Article


1 Department of Forensic Medicine and Clinical Toxicology, Medical Toxicology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

2 Department of Community Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

3 Department of Medical Genetics and Molecular Medicine, Vascular and Endovascular Surgery Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.


Introduction: Aluminum phosphide (AlP) poisoning, commonly known as rice tablet poisoning, is a lethal method of suicide with no known antidotes. Thyroid hormones have inotropic effects that can potentially reverse hemodynamic instability and improve cardiac output. This study investigated the effects of Triiodothyronine (T3) on the cardiac function of patients with aluminum phosphide poisoning.
Methods: In this randomized clinical trial, 24 patients with confirmed ALP poisoning were recruited. The intervention group received T3 treatment in addition to standard treatment, while the control group received only standard treatment. Demographic variables, cardiac parameters, biochemical markers, and oxidative stress tests were evaluated.
Results: The majority of participants were men (60%) in their thirties (intervention: 32±17.4 years; control: 30±11.6 years). Following treatment, both systolic and diastolic blood pressures had significantly higher mean differences in the T3 group compared to the control group (18.7±9.3, P=0.05 and 14.1±5.9, P=0.03 respectively). While both groups showed improvement in mean arterial pH, the intervention group exhibited a significantly greater improvement 12 hours after the administration of T3, which was significantly different from both the baseline and control groups (p=0.04, 0.009 respectively). Additionally, the intervention group had a lower QRS and QTc interval compared to admission time.
Conclusion: Triiodothyronine administration has been shown to maintain a higher range of SBP, control cardiogenic shock, regulate metabolism, improve acidosis and blood pressure, and ultimately enhance recovery in patients with aluminum phosphide poisoning. Furthermore, it may have cardio-protective effects on these patients.


  1. Hosseini, S.F., Forouzesh, M., Maleknia, M. et al.The Molecular Mechanism of Aluminum Phosphide poisoning in Cardiovascular Disease: Pathophysiology and Diagnostic Approach. Cardiovasc Toxicol 20, 454–461 (2020).
  2. Ghonem MM, El Sharkawy SI, Lashin HI. Predictive variables of acute aluminum phosphide poisoning outcome: a new proposed model. The Egyptian Journal of Forensic Sciences and Applied Toxicology. 2020 Jun 1;20(2):45-60.
  3. Sciuto AM, Wong BJ, Martens ME, Hoard-Fruchey H, Perkins MW. Phosphine toxicity: a story of disrupted mitochondrial metabolism. Annals of the New York Academy of Sciences. 2016;1374(1):41.
  4. Abdolghaffari AH, Baghaei A, Solgi R, Gooshe M, Baeeri M, Navaei-Nigjeh M, et al. Molecular and biochemical evidences on the protective effects of triiodothyronine against phosphine-induced cardiac and mitochondrial toxicity. Life sciences. 2015;139:30-9.
  5. Bajwa SJS, Bajwa SK, Kaur J, Singh K, Panda A. Management of celphos poisoning with a novel intervention: A ray of hope in the darkest of clouds. Anesthesia, essays and researches. 2010;4(1):20.
  6. Asghari MH, Moloudizargari M, Baeeri M, Baghaei A, Rahimifard M, Solgi R, Jafari A, Aminjan HH, Hassani S, Moghadamnia AA, Ostad SN. On the mechanisms of melatonin in protection of aluminum phosphide cardiotoxicity. Archives of toxicology. 2017 Sep;91:3109-20


  1. Bagherian F, Kalani N, Rahmanian F, Abiri S, Hatami N, Foroughian M, Mehramiz NJ, Shahi B. Aluminum phosphide poisoning mortality rate in Iran; a systematic review and meta-analysis. Archives of academic emergency medicine. 2021;9(1).
  2. Soltaninejad K, Nelson LS, Bahreini SA, Shadnia S. Fatal aluminum phosphide poisoning in Tehran-Iran from 2007 to 2010. Indian J Med Sci. 2012 Mar 1;66(3-4):66-70.
  3. Karimani A, Mohammadpour AH, Zirak MR, Rezaee R, Megarbane B, Tsatsakis A, et al. Antidotes for aluminum phosphide poisoning–An update. Toxicology reports. 2018;5:1053-9.
  4. Halvaei Z, Tehrani H, Soltaninejad K, Abdollahi M, Shadnia S. Vitamin E as a novel therapy in the treatment of acute aluminum phosphide poisoning. Turkish journal of medical sciences. 2017;47(3):795-800.
  5. Hamilton MA, Stevenson LW, Fonarow GC, Steimle A, Goldhaber JI, Child JS, Chopra IJ, Moriguchi JD, Hage A. Safety and hemodynamic effects of intravenous triiodothyronine in advanced congestive heart failure. The American journal of cardiology. 1998 Feb 15;81(4):443-7.
  6. Pingitore A, Galli E, Barison A, Iervasi A, Scarlattini M, Nucci D, L’Abbate A, Mariotti R, Iervasi G. Acute effects of triiodothyronine (T3) replacement therapy in patients with chronic heart failure and low-T3 syndrome: a randomized, placebo-controlled study. The Journal of Clinical Endocrinology & Metabolism. 2008 Apr 1;93(4):1351-8.
  7. Goharbari M, Taghaddosinejad F, Arefi M, Sharifzadeh M, Mojtahedzadeh M, Nikfar S, et al. Therapeutic effects of oral liothyronine on aluminum phosphide poisoning as an adjuvant therapy: A clinical trial. Human & experimental toxicology. 2018;37(2):107-17.
  8. Rezuş C, Moga VD, Ouatu A, Floria M. QT interval variations and mortality risk: is there any relationship? Anatol J Cardiol. 2015 Mar;15(3):255-8. doi: 10.5152/akd.2015.5875. PMID: 25880179; PMCID: PMC5337065.
  9. Barañano DE, Rao M, Ferris CD, Snyder SH. Biliverdin reductase: a major physiologic cytoprotectant. Proceedings of the national academy of sciences. 2002;99(25):16093-8.